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Abstract
The impairment of axonal transport by overexpression or hyperphosphorylation of tau is well
documented for in vitro conditions; however, only a few studies on this phenomenon have been
conducted in vivo, using invasive procedures, and with contradictory results. Here we used the
non-invasive, Manganese-Enhanced Magnetic Resonance Imaging technique (MEMRI), to study
for the first time a pure model of tauopathy, the JNPL3 transgenic mouse line, which
overexpresses a mutated (P301L) form of the human tau protein. We show progressive
impairment in neuronal transport as tauopathy advances. These findings are further supported by a
significant correlation between the severity of the impairment in neuronal transport assessed by
MEMRI, and the degree of abnormal tau assessed by histology. Unlike conventional techniques
that focus on axonal transport measurement, MEMRI can provide a global analysis of neuronal
transport, i.e. from dendrites to axons and at the macroscopic scale of fiber tracts. Neuronal
transport impairment has been shown to be a key pathogenic process in Alzheimer’s disease and
numerous other neurodegenerative disorders. Hence, MEMRI provides a promising set of
functional biomarkers to be used during preclinical trials to facilitate the selection of new drugs
aimed at restoring neuronal transport in neurodegenerative diseases.
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1. Introduction
Tauopathies are neurodegenerative diseases defined by the pathological accumulation of
filamentous tau in the central nervous system. Tau is a microtubule-associated protein
predominantly expressed in the axonal compartment of neurons, where it promotes
microtubule assembly and stabilization. Among tauopathies, the most frequent by far is
Alzheimer’s disease, followed by progressive supranuclear palsy, corticobasal degeneration
and Pick’s disease.
In these tauopathies, tau becomes abnormally phosphorylated, accumulates in the somato-
dendritic compartment of neurons and aggregates into neurofibrillary tangles The in vitro
evidence that abnormally phosphorylated tau is less able to stabilize microtubules
(Bramblett et al., 1993; Drechsel et al., 1992; Grundke-Iqbal et al., 1986; Iqbal et al., 1986)
led to the formulation of the “tau-microtubule” hypothesis, which states that tau
phosphorylation provokes microtubule breakdown, causing axonal transport impairment and
subsequent synaptic dysfunction (Iqbal and Grundke-Iqbal, 1991; Lee and Trojanowski,
1992). Studies in cellular models (Dayanandan et al., 1999; Lovestone et al., 1996) and in a
drosophila model of tauopathy (Cowan et al., 2010; Mudher et al., 2004) have confirmed
that tau phosphorylation can induce microtubule breakdown. An alternative hypothesis
states that the overexpression of normal, non-phosphorylated tau can impair axonal
trafficking by stearic hindrance of motors proteins, as shown in vitro (Dixit et al., 2008;
Seitz et al., 2002; Vershinin et al., 2007) and in cells (Ebneth et al., 1998; LaPointe et al.,
2009; Mandelkow et al., 2003; Stoothoff et al., 2009; Trinczek et al., 1999); tau
phosphorylation being considered as a compensatory mechanism which aims at rescuing
axonal transport (Falzone et al., 2010; Falzone et al., 2009; Vossel et al., 2010). Regardless
of the exact mechanism, both normal and hyperphosphorylated tau can aggregate and
thereby impair axonal transport during the course of the disease. Importantly, axonopathy
and transport deficits appear to occur early in the pathogenesis of AD and related mouse
models (Stokin et al., 2005).
These effects of pathological tau on axonal transport, as mentioned above, are described at
the microscopic scale of individual axons either ex vivo or in vitro and using cell culture and
drosophila model system. However, they may not be relevant at the macroscopic scale of
fiber tracts. The complexity of neuronal networks, and the various interactions that exist
between glial and neuronal cells, make one cautious when interpreting the results of single-
axon studies and inferring their relevance to the mammalian brain. Hence, the effects of
tauopathy on axonal transport need to be assessed at the macroscopic level using
mammalian models. Only a few axonal transport studies have been conducted in mouse
models of tauopathy, and their results have been contradictory. Two studies performed in
transgenic mice expressing normal human tau showed either retarded (Ishihara et al., 1999)
or normal axonal transport (Yuan et al., 2008). Two additional reports using transgenic mice
expressing mutant human tau found some evidence of impairment in axonal transport (Ittner
et al., 2008; Zhang et al., 2004), although one of those was limited to the transport of tau
itself, and not organelles and cargo proteins (Zhang et al., 2004). None of these studies
established a quantitative correlation between the level of abnormal tau and the degree of
axonal impairment. Indeed, there is still a need to prove in vivo that axonal transport deficits
represent a significant event during the course of tauopathy.
The reason for the contradictory findings to date on axonal transport in mouse models of
tauopathy may be related to the models employed, but also to the technical challenges of
measuring axonal transport. These prior studies in mouse models required invasive
techniques, such as a nerve ligation or injection into the spinal cord. Nerve ligation induces
nerve injury and local ischemia, which may interfere with normal axonal transport (Ittner et
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al., 2008; Zhang et al., 2004). Injection of radiolabelled amino acids requires deep surgical
procedures which can also induce ischemic-hemorrhagic changes in the area of interest
(Zhang et al., 2004; Zhang et al., 2005). Both these techniques rely on a post-mortem
quantification of the transported cargoes, and thus can only evaluate transport mechanisms
at a single time point for each animal. Lastly and importantly, these transport measurements
have always been done in the axonal compartment, as it is technically easier to access than
the dendritic trees. However, it is well known that pathological tau accumulation takes place
in the somato-dendritic compartment of neurons (Lee et al., 2001). Hence, the ideal
approach for the study of active transport in mouse models of tauopathy would provide a
non-invasive, longitudinal quantification of transport in all neuronal compartments (i.e.
soma, dendrites and axons), thus giving a comprehensive, 4D picture of neuronal transport
in fiber tracts.
Manganese-Enhanced MRI (MEMRI) is a non-invasive imaging technique based on the
physicochemical properties of manganese. As a calcium-analogue, manganese enters
neurons via Ca2+ channels (Drapeau and Nachshen, 1984; Lu et al., 2007; Narita et al.,
1990; Sloot and Gramsbergen, 1994), is transported along the microtubule system by active
transport partially dependent on kinesin (Bearer et al., 2007a; Sloot and Gramsbergen, 1994;
Smith et al., 2007; Takeda et al., 1998b), is released at the synaptic cleft (Takeda et al.,
1998b), and is taken up by the post-synaptic neuron (Saleem et al., 2002; Takeda et al.,
1998a; Tjalve et al., 1996; Tjalve et al., 1995). Thanks to its paramagnetic properties,
manganese causes a local increase of MR signal intensity in neurons that can be detected on
T1-weighted images (Lin and Koretsky, 1997). Hence, by repeated MR examinations over
time, the displacement of manganese in neurons can be dynamically monitored (Pautler and
Koretsky, 2002; Pautler et al., 1998). For these reasons, MEMRI can be used as a non-
invasive in vivo tool to study neuronal transport in animal models, either in the visual
system using intraocular injection of manganese (Bearer et al., 2007a), in the olfactory
system using intranasal delivery of manganese (Cross et al., 2008; Smith et al., 2007), in
deep fiber systems using intracerebral injection of manganese (Bearer et al., 2007b), or in
peripheral nerves following topical injection of manganese. (Matsuda et al., 2010). MEMRI
studies of the olfactory system have reported an in vivo impairment of axonal transport in
transgenic mouse model of amyloid β deposition (Massaad et al.; Smith et al., 2007; Smith
et al., 2010a) and in a triple transgenic mouse model with both amyloid β deposition and
neurofibrillary tangles (Kim et al., 2011). One MEMRI study of the olfactory system
focusing on the interaction between APP and tau included a subgroup of animals expressing
human mutated tau. Results from this subgroup suggested an in vivo impairment of axonal
transport related to tauopathy. However this study did not comprise any assessment of
pathological tau in the brain of the animals (Smith et al., 2010b).
Our goal was to examine by MEMRI a mouse model of tauopathy to address the following
questions:
• Can we detect in vivo an effect of mutant human tau on neuronal transport?
• Can we correlate these alterations of neuronal transport with the degree of
tauopathy, thus providing a functional biomarker of pathological tau in mice?
2. Material and Methods
2.1. Animals
Imaging experiments were performed on homozygous JNPL3 transgenic mice (Taconic;
(Lewis et al., 2000)) and wild-type (WT) control mice of the same strain background.
(C57BL/6, DBA/2 and SW mixed background). In this homozygous model, tau pathology
becomes evident around 2-3 months of age and is severe at 9 months (Asuni et al., 2007). 25
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animals (13 Tg and 12 WT) were imaged and monitored longitudinally at 3, 6 and 9 months
of age. To examine if there was a correlation between the extent of tauopathy and changes in
axonal transport, mice were euthanized and sacrificed at each of the selected time points: 8
animals (4 Tg and 4 WT) after the 3-month old examination, 10 animals (5 Tg and 5 WT)
after the 6-month old examination, and 7 animals (4 Tg and 3 WT) after the 9-month old
examination. In addition, to control for possible confounding effects related to the
potentially cumulative neurotoxicity of manganese, a supplementary group of 10 mice (5 Tg
and 5 WT) was examined at 9 months only and then euthanized. Each group of mice
included comparable number of males and females. A total of 35 animals were used for the
study. Procedures were performed in accordance with the Institutional Animal Care and Use
Committee at the New York University School of Medicine.
2.2. MnCl2 administration and MR scanning
MnCl2 (1.5 μL of 5M MnCl2) was administered under anesthesia (5% isoflurane) into one
nostril of the mouse using a micropipette under microscopic control. Mice were maintained
under anesthesia for 1 minute after the Mn administration, in order to delay the cough reflex
and to ensure a correct penetration of Mn in the nasal epithelium. Still, cough reflex did
occur in most of the animals after the anesthesia, and may have caused some variation in the
exact volume of manganese delivered; however, these random variations were equally likely
to occur in both WT and Tg animals. After the instillation, each mouse was allowed to
recover for a few minutes on a heating pad, and was then transferred to its cage.
During each imaging time course set, mice were scanned 9 times: once before manganese
injection, 7 times during the 2 days following the injection (at 1, 4, 8, 12, 24, 36 and 48h
after injection), and finally 7-10 days after the injection. MRI scans were performed on a 7T
micro-MRI system, consisting of a 200-mm horizontal bore magnet (Magnex Scientific,
UK) with an actively shielded gradient coil insert (Bruker BGA-9S; ID 90-mm, 750-mT/m
gradient strength, 100-μs rise time). The same in-house birdcage quadrature coil was used
for all image acquisitions (ID=22mm, length 29mm). Each scan consisted of a 3D T1-SPGR
sequence with the following parameters: FOV = 19.2 × 19.2 × 9.6 mm, matrix size = 128 ×
128 × 64, spatial resolution = (150μm)3, TR/TE = 15/4 ms, averages = 6, acquisition time =
15 min. Flip angle (18°) was chosen to provide the greatest T1-enhancement contrast
(Neelavalli and Haacke, 2007). Ten minutes before MR imaging, each mouse was
anesthetized with 5% isoflurane, and then placed in an in-house holder system including a
tooth bar, in order to maintain the head in a reproducible and stationary position in the coil.
During MR imaging, each mouse was kept under anesthesia using isoflurane in air (1-2%),
its body temperature being maintained at 35-37°C with a heated waterbed, and its
respiratory rate being constantly monitored. The level of isoflurane was continuously
adjusted so that the respiratory rate was always between 40 and 60 per minute. After MR
imaging, each mouse was allowed to recover on a heating pad for a few minutes, and was
then transferred back to its cage until the next scan. The total time under anesthesia for each
mouse did not exceed 30 min per scan.
2.3. MR image processing
All the MR datasets were processed using the ImageJ software (NIH, Rockville, MD). A
rigid registration was systematically performed between the MRI datasets acquired serially
from each individual mouse at 9 different time points using an automatic registration with
the Rigid_Registration.jar plugin (J Schindelin, M Longair). Unlike inter-subject
registration, the intra-subject realignment assessed for the 9 set of image time points proved
effective since it is less prone to anatomical mis-registration minimizing translation
requirement. Four regions of interest (ROI) were defined on the following structures using a
mouse brain atlas: the glomerular layer, the mitral cell layer, the anterior part of the piriform
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cortex, and the pons; the latter was used to normalize signal intensities at each time point
(see supplementary Fig.8).
The contralateral side was not used for normalization as some degree of enhancement was
observed in about half of the animals in similar proportion in both Tg and WT groups. For
each mouse, the normalized signal intensities in each ROI were plotted and fitted to a
previously described tract-tracing bolus model (Cross et al., 2008) using an in-house Matlab
fitting routine (The Mathworks 2009). Briefly, the manganese transport was assumed to
follow a drift/diffusion model described by the one-dimensional Fokker-Planck equation.
The parameters defining the time-intensity curves acquired experimentally were extracted
using a nonlinear least square fitting based on the Levenberg Marquardt algorithm. For each
mouse, the parameter of global scaling, reflective of the initial neuronal uptake of
manganese, was estimated by fitting in only the glomerular layer ROI, which was the closest
ROI to the site of infusion; the same value was subsequently used in the two downstream
ROI (mitral cell layer and anterior piriform cortex). The fitting process allowed us to
determine the curve profile of normalized signal intensity changes in each ROI as a function
of time, which reflects the local variations in manganese concentration over time (Wood and
Hardy, 1993). From the fitted curves, we extracted the following parameters: value of the
peak of intensity (Pv), time-to-peak of intensity (Pt), and maximal value of the ascending
slope (Sv).
2.4. Histology
These procedures were performed as previously described in detail (Sigurdsson, 2005).
Briefly, following MR examinations, the animals were terminally anesthetized with
ketamine and xylazine (300 mg/kg Ketamine + 60 mg/kg Xylazine i.p.) and perfused
transaortically with phosphate buffered saline. The right half of the brains, including right
olfactory bulbs, were used for this study and were immersion fixed overnight in 2%
periodate-lysine-paraformaldehyde solution (PLP), and subsequently placed in 2% DMSO/
20% glycerol in phosphate-buffered saline (PBS) overnight or until sectioned. Serial coronal
sections (40 μm) were cut in a cryostat, and four series of every tenth section were used for
staining. Sections were stored at -30°C in an ethylene glycol cryoprotectant until used for
histology.
Immunohistochemistry was performed as previously described (Sigurdsson, 2005). Briefly,
following several washes in PBS, free-floating sections were incubated in 0.3% H2O2 for 15
min to block endogenous peroxidase activity, and then placed in a blocking solution for 1 h
at room temperature, to block nonspecific binding. The blocking solution consisted of: 1)
5% milk in TBS (PHF1); 2) A mouse-on-mouse (MOM) blocking reagent from the MOM
immunodetection kit (Vector Laboratories, Burlingame, CA; MC1); 3) A polyclonal
antibody diluent solution with 2% bovine serum albumin and 10% goat serum (GFAP). The
sections were then incubated overnight in the primary antibodies (see below Antibodies for
immunohistochemistry). The biotinylated IgG secondary antibody and the avidin and
peroxidase solutions (anti-mouse or anti-rabbit antibody, Vector Laboratories, Elite Kits,
Burlingame, CA) were used at a 1:1000 dilution. Antibody staining was revealed with 3,3’-
diaminobenzidine tetrahydrochloride (Sigma) with nickel ammonium sulfate (Mallinckrodt,
Paris, KY) intensification. The sections were then mounted onto slides, air-dried, dehydrated
and defatted, cleared in CitriSolv (Fisher Scientific), and cover slipped with Depex
mounting media.
For neuronal counting, sections were stained with cresyl violet. Sections were first mounted
onto slides, air-dried, defatted, progressively rehydrated and stained for 75 seconds in a
solution of 0.1% cresyl violet (Sigma) in 0.01 M acetic acid, then dehydrated, cleared in
CitriSolv (Fisher Scientific), and cover slipped with Depex mounting media.
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2.5. Antibodies for immunohistochemistry
PHF1 and MC1 monoclonal antibodies (kindly provided by Dr. Peter Davies) were used at
1:2500 (PHF1) or 1:50 (MC1) dilution. PHF1 IgG1 antibody recognizes phosphorylated
serine 396 and 404 located outside the microtubule-binding repeat on the C terminal of the
tau protein (Otvos et al., 1994). MC1 antibody is a conformation dependent IgG1 antibody
that is similar to Alz-50 (IgM). Its reactivity depends on both the N terminus (amino acids
7–9), and an amino acid sequence of tau (amino acids 313–322) in the third microtubule
binding domain that is both necessary and sufficient for in vitro formation of filamentous
aggregates of tau similar to those seen in AD. However the pathological conformation of tau
recognized by MC1 seems to precede the aggregation of tau into filaments and the resultant
neurofibrillary degeneration (Jicha et al., 1999). Both antibodies recognize tau pathology in
the JNPL3 mouse model (Lewis et al., 2000). GFAP polyclonal antibody (Dako, Glostrup,
Denmark) was used at 1:1000. GFAP antibody recognizes the glial fibrillary acidic protein,
a 50 kDa intracytoplasmic filamentous protein that constitutes a portion of the cytoskeleton
in astrocytes, and has been shown to be the most specific marker for cells of astrocytic
origin (Eng et al., 2000)
2.6. Quantification of MC1, PHF1 and GFAP staining
In order to correlate MEMRI parameters with the expression of mutant human tau, we
quantified the level of staining in 3 areas (Fig1): 1) The mitral cell layer, which corresponds
to our second ROI on MR images and contains the cell bodies of mitral cells; 2) The
external plexiform layer, which is located just upstream of the mitral cell layer and contains
the dendritic processes of mitral cells, and 3) The anterior piriform cortex, which
corresponds to our third ROI on MR images, and contains cell bodies and axonal/dendritic
processes of cortical neurons. In the glomerular layer, which was our first ROI on MR
images, the degree of staining was not accurately quantifiable because of high level of non-
specific staining at the edges of the olfactory bulb.
Quantitative analysis of tissue sections was performed using the ImageJ software (NIH,
Rockville, MD). Six sections were analyzed per animal and per antibody stain (PHF1, MC1,
GFAP), every 2 sections corresponding to each ROI (external plexiform layer, mitral cell
layer, anterior piriform cortex). After digitization, sections were analyzed based on the same
rectangular ROI manually placed within the layer of interest. A segmentation threshold was
visually established to accurately identify staining in these areas. The measurement
consisted of the fractional stained area in each ROI at 200X magnification (20X objective).
2.7. Cell counting
Cell counting was first performed in all ROI using a semi-quantitative method, by a visual
ranking of cell density on a score of 1 to 4. Subsequently, unbiased neuronal counting was
performed in the mitral cell layer of all animals. The mitral cell layer was chosen because of
its easy delineation on coronal sections, which allows for cell counting in the whole layer.
We used stereological image analysis software (StereoInvestigator 10, MicroBrightField
Bioscience, Williston, VT) controlling a Ludl motorized stage in a Leica DM5000B
microscope. The edges of the mitral cell layer were traced at low power (200 magnification,
20X objective) and counting frames of 225 μm2 were selected at random on a sampling grid
by the image analysis software. Twelve to twenty counting frames were used on each
section, representing 5% of the total area of the mitral cell layer visible on the corresponding
section. Neurons were counted through a 100X objective with the optical fractionator
method. Three to four sections per animal were analyzed. Final estimated cell counts in the
mitral cell layer were expressed as number of neurons per mm3.
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2.8. Statistical analysis
All the data were analyzed with GraphPad (San Diego, CA) Prism 5.0. Functional
parameters of manganese propagation extracted from fitted MRI data (Pv, Pt, Sv),
immunoreactivity on brain sections and cell density in the mitral cell layer were compared
by two-tailed t test, either unpaired (comparing WT and Tg at the same age) or paired
(comparing same animals at 3 and 6 months of age), except when the data failed at least two
of the three normality tests (D’Agostino and Pearson, Shapiro–Wilk and Kolmogorov-
Smirnov normality tests) or the F test to compare variances. In these cases data were
compared using Mann-Whitney test (comparing WT and Tg at the at the same age) or the
Kruskall-Wallis test (comparing same animals at 3 and 6 months of age). Correlations
between functional parameters of manganese propagation and tau pathology were assessed
by Pearson correlation coefficient, except when the data failed at least two of the three
normality tests or the test of equal variances, in these cases correlations were assessed using
the non parametric Spearman correlation coefficient. Due to typical variations in the degree
of tau pathology observed in this mouse model between age-matched Tg animals, we
considered only the 17 animals that were imaged both at 3 and 6 months of age for the
analysis of the functional parameters defining the manganese propagation (Pv, Pt, Sv),
3. Results
3.1. MEMRI detects an age-related impairment of manganese propagation in the olfactory
system of JNPL3 tauopathy mice
Curve profiles of normalized signal intensities, reflective of manganese propagation, were
similar between WT and Tg at 3 months of age, but showed marked differences at 6 months
of age, for both the glomerular layer (Fig. 2, A&B) and the mitral cell layer (Fig. 3, A&B).
The fitting process performed in each mouse allowed us to analyze 3 parameters: the value
of the peak of signal intensity (Pv), the time-to-peak of signal intensity (Pt), and the
maximal value of the ascending slope of signal intensity (Sv) (Fig.2&3 C-E). In our first
ROI, the glomerular layer, all 3 parameters were significantly altered in Tg animals between
3 and 6 months of age: Pv was decreased, Sv was decreased and Pt was delayed (Fig.2 C-E).
In our second ROI, the mitral cell layer, curve profiles were globally lower than in the
glomerular layer, but the same significant phenomena was observed (Fig 3 C-E). In our third
ROI, the piriform cortex, curve profiles were even lower, and significant differences were
not obtained neither when comparing age, nor when comparing Tg vs. WT mice (data not
shown).
3.2. Manganese transport dynamics, reflective of neuronal transport, correlates with the
degree of tau pathology in the olfactory system of JNPL3 tauopathy mice
We compared the observed modifications in MEMRI parameters (Pv, Pt and Sv) with the
degree of tau pathology in the corresponding neurons. Tau pathology could not be reliably
quantified in the glomerular layer because of high levels of non-specific staining within this
region; thus, we focused for this analysis on the mitral cells. The degree of staining was
assessed in the external plexiform layer, which corresponds to the dendritic compartment of
mitral cells, and in the “mitral cell layer” proper, which corresponds to the somatic
compartment of mitral cells (Fig.4, and supplementary Fig. 9 A-H). In both compartments,
MC1 and PHF1 immunoreactivity (IR) were higher in the Tg animals than in WT controls.
PHF1 IR did not differ as robustly as MC1 IR, likely because of a moderate PHF1 IR in WT
animals (Fig 4 B&D, p<0.05).
The peak of signal intensity (Pv) was the MEMRI parameter that demonstrated the strongest
correlation with the degree of tauopathy (Fig.5 A-D). Pv correlated significantly with the
level of somatic PHF1 and MC1 IR (Fig.5A&B, r=-0.38, p < 0.05 and r=-0.46, p < 0.01
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respectively), and even more strongly with the level of dendritic PHF1 and MC1 IR (Fig.
5C&D, r=-0.5, p < 0.005 for both). A threshold of 1.85 for the peak value allowed the
separation of all Tg animals with MC1-positive dendrites (stained area >0.5%), from all Tg
animals with low levels of MC1 dendritic staining (stained area <0.1%) and all except one
WT animal (Fig. 5.D). When considering only the group of Tg animals, correlations were
not significant between Pv and somatic PHF1 staining, dendritic PHF1 staining or somatic
MC1 staining, but was highly significant between Pv and dendritic MC1 staining (r=-0.78,
p=0.0002).
Among the two other parameters (Sv and Pt), only Sv showed a significant correlation with
the level of somatic and dendritic MC1 IR (r=-0.44, p<0.01 and r=-0.45, p<0.01
respectively). The correlation of Sv with dendritic MC1 IR remained significant when
considering the group of Tg animals only (r=-0.50, p< 0.05, data not shown).
3.3. WT and Tg JNPL3 tauopathy mice did not differ in the number of glial cells and
neurons in the olfactory system, further supporting that the observed differences in Mn
dynamics are caused by perturbations in neuronal transport
It is well-known that in addition to its transport in neurons, manganese can also be stored in
astrocytes (Aschner et al., 1999; Chan et al., 2008). Thus, we quantified the degree of GFAP
staining in the olfactory bulbs of Tg and WT animals to rule out confounding influence of
astrogliosis in the Tg group. GFAP staining was comparable between WT and Tg animal at
all ages, both in the external plexiform layer and in the mitral cell layer (Fig.6 A&B, and
supplementary Fig. 9 I-L).
Another potentially confounding variable to consider is a possible neuronal loss in the
olfactory system of the tauopathy animals. To investigate this, we performed a semi-
quantitative evaluation of neuronal density in the olfactory system of Tg and WT animals,
by visual ranking. No significant difference was observed between Tg and WT in neuronal
density within the glomerular layer, the mitral cell layer and the anterior piriform cortex at 3
and 6 month-old (data not shown). To definitely rule out neuronal loss in Tg animals, we
performed an unbiased stereological quantification of neurons in the mitral cell layer of all
animals. The average number of neurons per mm3 did not differ significantly between 3 and
6 month-old Tg mice, or between 6 month-old Tg mice and age-matched WT (Fig.6 C, and
supplementary Fig. 9 M-P).
3.4. Comparison of animals that underwent one single examination at 9 months of age,
and those that were examined at 3, 6 and 9 months of age, suggests that the amount of
administered manganese was not neurotoxic
We did not observe significant difference in MEMRI parameters (Pv, Pt and Sv) or in
histological characteristics (MC1, PHF1 and GFAP staining, neuronal density) between the
subgroup of 9 month-old animals which were examined only once, and the subgroup of 9
month-old animals that were examined repeatedly at 3, 6 and 9 months of age, thus
receiving three times more manganese (Fig.7).
4. Discussion
This in vivo study demonstrates an impairment of manganese propagation within the
olfactory system of TgJNPL3 mice. Manganese propagation has been shown in the literature
to be dependent on active axonal transport (Bearer et al., 2007a; Sloot and Gramsbergen,
1994; Smith et al., 2007; Takeda et al., 1998b). In pathological conditions, other
phenomenon such as neuronal loss or gliosis could also impair neuronal transport, but we
showed that these were absent in the TgJNPL3 mice we studied as compared to controls.
Lastly, the significant correlations between manganese propagation parameters and levels of
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tauopathy in neurons assessed by immunohistochemistry strongly support the fact that
manganese transport reflects active neuronal transport in our study. Thus, our results
demonstrate for the first time an in vivo impairment of neuronal transport related to the
expression of mutant human tau in JNPL3 mice. Our results are in agreement with previous
studies obtained in other transgenic animal models of tauopathy, expressing R406W (Zhang
et al., 2004) and K369I (Ittner et al., 2008) mutant human tau, in which invasive techniques
were used to quantify axonal transport in spinal cord and peripheral nerves. Significantly,
our protocol provides a non-invasive estimation of neuronal transport in the mouse brain,
thus being more relevant for the study of tauopathies. Using a long time-frame MEMRI
protocol, we were able to acquire serial 3D data set with 150μm isotropic spatial resolution
and estimate the entire curve profile of manganese transport. This enabled us to calculate
retrospectively different parameters of transport (i.e. peak value, maximal slope and time-to-
peak) in any desired pixels within the olfactory tract in which manganese propagates.
Although the physical meaning of each parameter remains to be studied further, these
measurements are very useful. The peak value gave the highest statistical significance for
the comparison of WT and Tg animals (Fig. 2C & 3C), whereas the maximal slope was the
best parameter to monitor Tg mice during aging (Fig 2D & 3D). These differences highlight
the advantages afforded by the acquisition of the long time-frame protocol we used, which
gives access to all parameters of manganese transport (Cross et al., 2008). In contrast, short
time-frame protocols are more widely used in mice, less time-consuming, and do not require
any image registration; but they are limited to the analysis of an anatomical region
predefined experimentally using a single parameter, the slope of manganese progression
(Kim et al., 2011; Massaad et al.; Smith et al., 2007; Smith et al., 2010a). Moreover, during
short-time frame protocols, neuronal transport is studied during the acquisition of MR
images, i.e. when the mouse is still and anesthetized. In contrast, long time-frame protocols
spanning over multiple sessions enable the overall displacement of manganese to occur in-
between MR acquisitions while mice are fully awake and active within their usual
environment; hence this allows the characterization of manganese transport under near
physiological conditions.
In this study, we were able for the first time to correlate MEMRI parameters of neuronal
transport (i.e. peak value and maximal slope) with a histological hallmark of a neurological
disease, namely tau aggregates in neurons. Thus, our non invasive, in vivo and 4D approach
provides a set of functional biomarkers of taupathy in transgenic mice. Predictably, this
correlation was stronger when looking at the degree of pathological tau in the dendrites of
neurons, than in the soma of neurons, as neuronal transport occurs mainly in dendrites and
axons. PHF1 staining did not correlate as well as MC1 staining with the MEMRI
measurements, which is likely related to PHF1 reactivity in normal tissue.
The strong correlation we obtained between MEMRI parameters and tau pathology in the
dendritic compartment stresses the importance of transport alterations occurring in dendrites,
which has not been investigated so far in tauopathies, as all studies have focused on the
axonal compartment of neurons. Indeed, the dendritic compartment is challenging to explore
even with videomicroscopy, because of the extreme tortuosity of dendritic branches as
compared to the linearity of axons. Thus, MEMRI provides a unique tool for the exploration
of neuronal transport at a global level, occurring from dendrites to axons.
The MEMRI technique we describe could be very useful for preclinical evaluation of new
therapies against AD and related tauopathies: MEMRI could assess the functional benefit of
therapeutic strategies for clearing pathological tau and/or for restoring a normal neuronal
function. In this regard, the set of preclinical functional biomarkers we have described may
be very useful for selecting efficient drugs against various neurodegenerative diseases such
as tauopathies.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig.1.
Regions of interest. Diagrammatic representation (left side) of the regions of interest placed
on MR images (right side, axial view of the mouse brain). On this T1-weighted sequence
performed 8h after nasal manganese injection, the areas of increased signal intensity (white
color) correspond to the anatomical regions in which Mn propagates along the olfactory tract
and accumulates transiently in high concentration (Pautler et al., 1998). The glomerular
layer and the mitral cell layer both appear as hyperintensity separated by a narrow
hypointense rim.
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Fig. 2.
Curve profiles of Mn transport in the glomerular layer were similar between Tg and WT at 3
months of age (A), but showed marked differences at 6 months of age (B) (raw data are
presented as inserts to depict the mean and standard deviation of all the subjects considered
in the fit). The fitting process enabled the extraction of curve parameters (i.e., peak value,
maximal slope and time-to peak) in each animal. Curve parameters of 6 month-old Tg
animals were significantly different from those of same animals at 3 months of age (C,
D&E), and from those of age-matched WT (C). Mean value is represented for each group,
with the standard error of the mean.
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Fig. 3.
Curve profiles of Mn transport in the mitral cell layer were similar between Tg and WT at 3
months of age (A), but showed marked differences at 6 months of age (B) (raw data are
presented as inserts including the mean and standard deviation of all the subjects considered
in the fit). Curve parameters of 6 month-old Tg animals were significantly different from
those of same animals at 3 months of age (C, D&E), and from those of age-matched WT
(C&D). Mean value is represented for each group, with the standard error of the mean.
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Fig.4.
Progression of tau pathology over time in the different regions of interest, evaluated by
immunohistochemistry (MC1 and PHF1 antibodies). Statistically significant differences are
observed when comparing tau pathology between the whole WT group and the whole Tg
group. A trend of increased pathology with age is observed in Tg animals; this trend does
not reach statistical significance because of the high inter-subject variability of pathology
expression which exists in this strain. (m.o. = month-old).
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Fig. 5.
Peak value measured in the mitral cell layer correlated significantly with tau pathology
(MC1 and PHF1 antibodies). Statistical significance was higher when considering dendritic
tau (C&D) than somatic tau (A&B). A threshold of 1.85 for the peak value allowed the
separation of all Tg animals with MC1-positive dendrites (stained area >0.5%), from all Tg
animals with low levels of MC1 dendritic staining (stained area <0.1%) and all except one
WT animal (Fig 5D).
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Fig. 6.
Levels of GFAP staining (A&B) did not differ significantly between WT and Tg animals at
all ages, ruling out the occurrence of astrogliosis in the Tg group. Unbiased cell counting in
the mitral cell layer (C) did not show any significant neuronal loss in the Tg group as
compared with WT.
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Fig. 7.
Comparison of MEMRI parameters (A&B) and histological characteristics (C-F) at 9
months of age, between the follow-up subgroup (mice injected and examined at 3, 6 and 9
months of age) and the vehicle subgroup (mice injected and examined at 9 months of age
only). No statistical difference was observed between the two subgroups for any of the
parameters.
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